Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405086 · ClinicalTrials.gov registry record · Phase 4
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
A Phase 4 study, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT07405086 is a Phase 4 study that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 160 participants.
The verdict
NCT07405086, a Phase 4 study, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 11:00 am) or afternoon (12:00pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Immune Checkpoint Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07405086
The ClinicalTrials.gov registry entry for NCT07405086 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT07405086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07405086 about?
NCT07405086 is a clinical study titled "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study". This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)...
What is the current status of trial NCT07405086?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2026-06-08. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07405086?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Immune Checkpoint Inhibitor (DRUG).
Who is sponsoring clinical trial NCT07405086?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.